{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/sickle-cell-disease/management/screening/","result":{"pageContext":{"chapter":{"id":"e76854fe-5d45-5d85-8591-5712daa7e4d9","slug":"screening","fullItemName":"Scenario: Screening","depth":2,"htmlHeader":"<!-- begin field b03c9acf-ea8a-4083-bf26-0fcd8ec7dc13 --><h2>Scenario: Screening</h2><!-- end field b03c9acf-ea8a-4083-bf26-0fcd8ec7dc13 -->","summary":"Provides information on the national screening programme to detect sickle cell disease and other disorders, such as sickle cell trait and thalassemia.","htmlStringContent":"<!-- begin item c68426fe-e764-4069-a6a3-33a1da61dac2 --><!-- begin field e56e92c5-238d-4dd1-8198-acbd00886133 --><p>From birth onwards.</p><!-- end field e56e92c5-238d-4dd1-8198-acbd00886133 --><!-- end item c68426fe-e764-4069-a6a3-33a1da61dac2 -->","topic":{"id":"eb346bd0-1df2-5db2-a583-a366e34cfc19","topicId":"cc107f5d-efe6-4625-840e-5c4d4656869b","topicName":"Sickle cell disease","slug":"sickle-cell-disease","lastRevised":"Last revised in November 2016","chapters":[{"id":"d2b6d668-4d29-5c50-b65d-7467cbcce2dd","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"47f9af8d-8bda-55a3-bf81-eb75a7c4f02a","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"4a0ece3e-fa44-5ecd-9f55-ac17384d960c","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"44a5b5f9-fc8e-5024-87e3-a7e42dca3dd9","slug":"changes","fullItemName":"Changes"},{"id":"48757ec5-731a-57fd-8e39-d2cdf918179a","slug":"update","fullItemName":"Update"}]},{"id":"53ae2089-f545-5b24-99c5-a9fc620ea575","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"ffff20e4-5bc5-5c3b-bb59-858dba2fcf8d","slug":"goals","fullItemName":"Goals"},{"id":"16f85d1d-aec7-5173-9e0b-7d9456bdf3a5","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"12a41d5f-f447-5a64-868a-7648c7de9355","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"5de2a0f3-a77d-5244-a401-dbd2cbcfefb3","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"fc893fb4-51ec-5705-8dff-c7fba1969646","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"cc1cc5c4-df13-5e74-bde0-9f625ec4d1cf","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"02e2bd4f-75cd-5b59-9a81-c06d3bcf4d2f","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"2a8eb5f7-6691-505b-bd86-9620102057a3","slug":"definition","fullItemName":"Definition"},{"id":"b756c83a-dcc0-5792-b3f9-fa9416929ce3","slug":"prevalence","fullItemName":"Prevalence"},{"id":"488c0ab1-f1c0-5fbf-bd1e-e327181c2e1f","slug":"prognosis","fullItemName":"Prognosis"},{"id":"b62a5aae-0dc3-5ac0-a1b1-d3ca0a7969ac","slug":"complications","fullItemName":"Complications"}]},{"id":"9336c0e7-d5d3-5dd6-99fd-50610ced96e1","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"dd5a2bec-36ce-58c0-b0f1-4ec5d4d17c21","slug":"when-to-suspect-sickle-cell-disease","fullItemName":"When to suspect sickle cell disease"},{"id":"bdbf4e2a-7a0c-5a2e-8b9c-4a9c661409ef","slug":"diagnosis-of-sickle-cell-disease","fullItemName":"Diagnosis of sickle cell disease"},{"id":"68746f0d-607a-5db5-8949-a87a4ed29328","slug":"when-to-suspect-an-acute-sickle-cell-crisis","fullItemName":"When to suspect an acute sickle cell crisis"},{"id":"ed48dbda-a404-50cf-a290-86fafcdb9908","slug":"assessment-of-acute-crisis","fullItemName":"Assessment of acute crisis"}]},{"id":"221fb88b-b951-5835-b282-ed218b637ff0","fullItemName":"Management","slug":"management","subChapters":[{"id":"e76854fe-5d45-5d85-8591-5712daa7e4d9","slug":"screening","fullItemName":"Scenario: Screening"},{"id":"1da4d393-99a4-51c1-b354-f1742b9d8b1f","slug":"management-sickle-cell-crisis","fullItemName":"Scenario: Management - sickle cell crisis"},{"id":"2bf8553c-1641-5bdc-bbc3-2615ddc5b84c","slug":"management-chronic-complications","fullItemName":"Scenario: Management - chronic complications"},{"id":"4493185d-8907-5325-a195-a7cd7039bd68","slug":"prevention-of-complications","fullItemName":"Scenario: Prevention of complications"},{"id":"2aeac855-0e31-598c-804d-41c8d9bc643f","slug":"management-sickle-cell-trait","fullItemName":"Scenario: Management - sickle cell trait"},{"id":"5b85ac92-9286-564f-88fb-ec37a6f4102e","slug":"contraception","fullItemName":"Scenario: Contraception"}]},{"id":"a424bf70-c56c-54a4-a2e2-019ab7c27c69","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"515607d5-c2e2-5a4c-8d83-1bb5e320badf","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2148be5b-6502-5e45-b86b-e552aa3226fd","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"acc3b704-7f3d-51ed-869e-38e0309c53e5","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"2a46384b-d43c-536a-9a17-4b8953d8457a","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"46873f42-ab32-5894-b2fe-429a4e62161b","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"1dd24310-b8ac-5381-b51a-ca1f6c178d72","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"7405fe0a-8432-5e64-9fe0-4d112fd89232","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"221fb88b-b951-5835-b282-ed218b637ff0","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"2e8600e9-704e-5fe0-a0ca-0fb79e6ac39c","slug":"national-screening-programme","fullItemName":"National screening programme","depth":3,"htmlHeader":"<!-- begin field d0dae685-1dc0-4cdf-bb86-8b15f43df77c --><h3>What is the national screening programme for sickle cell disorders?</h3><!-- end field d0dae685-1dc0-4cdf-bb86-8b15f43df77c -->","summary":null,"htmlStringContent":"<!-- begin item 3c2c787b-85ff-45fa-9b5a-4f1c7d835c31 --><!-- begin field 4bc7c7e1-1b45-43b0-8a3f-4b792bea051f --><ul><li><strong>ln infants, guidelines from the <a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/402208/Standards2ndEdition__1_.pdf\" data-hyperlink-id=\"b9a236a4-9817-4d02-aefa-a8f701556cf3\">NHS Sickle Cell and Thalassaemia Screening Programme</a> advise that:</strong><ul><li>All newborn infants should be screened for sickle cell disease.</li><li>All infants younger than 1 year of age who have newly arrived in the UK should also be offered screening.<ul><li>In children aged 1 year and older, the awareness and vigilance of health professionals is relied on to ensure that appropriate testing is carried out in children from <a class=\"topic-reference internal-reference\" href=\"/topics/sickle-cell-disease/background-information/prevalence/\">at-risk ethnic groups</a>, if clinically indicated. </li></ul></li></ul></li><li><strong>In pregnant women, guidelines from the <a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/402208/Standards2ndEdition__1_.pdf\" data-hyperlink-id=\"b2250d86-3113-407e-9f1b-a8f701556d35\">NHS Sickle Cell and Thalassaemia Screening Programme</a> advise that:</strong><ul><li>In high-prevalence areas (more than 1.5 infants born with sickle cell disease per 10,000 births):<ul><li>All pregnant women should be offered screening for sickle cell, thalassaemia, and other haemoglobin variants, using routine blood cell indices and a <a href=\"http://sct.screening.nhs.uk/cms.php?folder=2506\" data-hyperlink-id=\"e376378d-b13e-4800-9003-a8f701556d64\">Family Origin Questionnaire (FOQ)</a> to assist with risk assessment of positive results.</li><li>For women identified as carriers, their baby’s father (irrespective of family origin) is offered testing for sickle cell, other haemoglobin variants, and thalassaemia. </li></ul></li><li>Low-prevalence areas (1.5 infants or less born with sickle cell disease per 10,000 births):<ul><li>All pregnant women should be offered screening for thalassaemia using routine red blood cell indices.</li><li>A <a href=\"http://sct.screening.nhs.uk/cms.php?folder=2506\" data-hyperlink-id=\"22f400ce-2897-4242-b5b1-a8f701556d80\">Family Origin Questionnaire (FOQ)</a> should be used to screen for the risk of either the woman or the baby’s father being a carrier for sickle cell and other haemoglobin variants. Women in high-risk groups or women whose baby’s father is in a high-risk group are offered laboratory testing for haemoglobin variants.</li><li>All fathers of babies of identified carrier mothers (irrespective of family origin) should be offered testing for sickle cell, other haemoglobin variants, and thalassaemia. </li></ul></li><li>A <a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/454859/HP_and_LP_Trusts_2015.pdf\" data-hyperlink-id=\"158b1dc3-a2f4-454d-baf1-a8f701556d85\">list of high and low prevalence trusts</a> is available on the GOV.UK website (<a href=\"https://www.gov.uk/government/publications/nhs-trusts-area-prevalence-for-sickle-cell-and-thalassaemia\" data-hyperlink-id=\"d4e0277a-75a6-4638-aea6-a8f701556db8\">www.gov.uk</a>). </li></ul></li><li><strong>Guidelines from the British Society for Haematology (BSH) advise that:</strong><ul><li><strong>In addition to the </strong><strong>guidelines of the NHS Sickle Cell and Thalassaemia Screening programme </strong><strong>the following people should be screened:</strong><ul><li>All people from <a class=\"topic-reference internal-reference\" href=\"/topics/sickle-cell-disease/background-information/prevalence/\">high-risk groups</a> who are about to undergo an operation or receive anaesthesia.</li><li>All women who are having assisted conception.</li><li>All women who are being investigated for infertility.</li></ul></li><li>Ideally, all women in high-risk groups for haemoglobinopathies should be screened before conception. If an abnormality is found, then partners should be offered testing.<ul><li>Pre-marriage screening for haemoglobinopathies is not usual in the UK, but for some religious or ethnic groups, pre-marital screening for beta-thalassaemia heterozygosity may be more acceptable than pre-conceptual or antenatal screening.</li></ul></li></ul></li></ul><!-- end field 4bc7c7e1-1b45-43b0-8a3f-4b792bea051f --><!-- end item 3c2c787b-85ff-45fa-9b5a-4f1c7d835c31 -->","subChapters":[{"id":"e2e5766d-3af4-55a6-b38a-038dce7c80e0","slug":"basis-for-recommendation-d99","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field e530e213-71d3-4332-84a0-ca3d35a86225 --><h4>Basis for recommendation</h4><!-- end field e530e213-71d3-4332-84a0-ca3d35a86225 -->","summary":null,"htmlStringContent":"<!-- begin item d99be9dd-7c84-4fe4-b19d-c014541675df --><!-- begin field 3a022ddf-08e1-4566-bd89-27067cae5516 --><h5>Screening infants and pregnant women</h5><ul><li>These recommendations are based on the NHS Sickle Cell and Thalassaemia Screening Programme <em>Standards for the linked Antenatal and Newborn Screening Programme</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">NHS Screening Programmes, 2011</a>], which aims to:<ul><li>'Support people to make informed choices during pregnancy and before conception'.</li><li>'Improve infant health through prompt identication of affected babies'.</li><li>'Provide high quality and accessible care throughout England'.</li><li>'Promote greater understanding and awareness of the diseases and the value of screening'. </li></ul></li></ul><h5>Screening other people</h5><ul><li>This recommendation is based on expert opinion in the guideline <em>Significant haemoglobinopathies: guidelines for screening and diagnosis</em> published on behalf of the British Society for Haematology [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">Ryan et al, 2010</a>], which states that:<ul><li>'Pre-conceptual testing is important because it can be difficult to complete antenatal screening and fetal diagnosis within the first 12 weeks of pregnancy if the couple is unaware of the risk'.</li><li>'Pre-conceptual testing should always be performed in women being investigated for infertility and in those having assisted conception. If a woman is found to have or be a carrier for a significant haemoglobinopathy, the partner or other sperm donor should be tested, if appropriate, and the women given counselling. If a donor ovum is to be used, the donor should be screened for relevant haemoglobinopathies'.</li></ul></li></ul><!-- end field 3a022ddf-08e1-4566-bd89-27067cae5516 --><!-- end item d99be9dd-7c84-4fe4-b19d-c014541675df -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}